IC50: 19.59 nM/L (insulin receptor)[2]
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes[1][2].
Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM/L[2].
Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells[2].
Western Blot Analysis[2]
| Cell Line: | HL-1 cardiomyocytes |
| Concentration: | 200 nM |
| Incubation Time: | 0-60 min |
| Result: | Decreased the level of Akt phosphorylation after 5 and 10 min treatment. |
Insulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia[1].
| Animal Model: | Male Swiss mice with diabetes[1] |
| Dosage: | 5 U/kg |
| Administration: | Subcutaneous injection; 5 U/kg once daily for 30 days |
| Result: | Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes. |
[1]. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219.
[2]. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul